BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 33344502)

  • 1. Systematic Analyses of the Role of the Reader Protein of
    Shao XY; Dong J; Zhang H; Wu YS; Zheng L
    Front Mol Biosci; 2020; 7():577460. PubMed ID: 33344502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel prognostic biomarker:
    Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J
    Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
    Wang H; Cai H; Li L
    Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
    Han X; Long W; Liu Y; Xu J
    Front Surg; 2022; 9():985034. PubMed ID: 36338652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma.
    Zhang Y; Hua X; Shi H; Zhang L; Xiao H; Liang C
    Cancer Cell Int; 2021 Dec; 21(1):680. PubMed ID: 34923969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.
    Xie S; Wang Y; Huang J; Li G
    IET Syst Biol; 2022 Feb; 16(1):1-17. PubMed ID: 34647424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constructing and validating of m7G-related genes prognostic signature for hepatocellular carcinoma and immune infiltration: potential biomarkers for predicting the overall survival.
    Liu P; Dong C; Shi H; Yan Z; Zhang J; Liu J
    J Gastrointest Oncol; 2022 Dec; 13(6):3169-3182. PubMed ID: 36636051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic, prognostic, drug sensitivity and ceRNA internet of
    Li X; Pan Y; Feng S; Xing W; Lin B; Li W; Li M; Zhu M
    Transl Cancer Res; 2024 Feb; 13(2):594-612. PubMed ID: 38482448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma.
    Wu J; Sun M; Li Z; Shen Y; Wu Y; Zhang H; Xu Z; Gao Q
    J Gastrointest Oncol; 2023 Jun; 14(3):1434-1450. PubMed ID: 37435232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Significance of
    Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00638/hsa-miR-29b-3p axis-mediated high expression of CDCA4 correlates with tumor immune infiltration and hepatocellular carcinoma progression.
    Wang B; Chen L; Li Q; Zhou J; Jin W
    Transl Cancer Res; 2023 May; 12(5):1290-1306. PubMed ID: 37304553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.